TY - JOUR
T1 - Perioperative mortality for radical cystectomy in the modern Era
T2 - experience from a tertiary referral center
AU - Sobhani, Sina
AU - Ghoreifi, Alireza
AU - Douglawi, Antoin
AU - Ahmadi, Hamed
AU - Miranda, Gus
AU - Cai, Jie
AU - Aron, Monish
AU - Schuckman, Anne
AU - Desai, Mihir
AU - Gill, Inderbir
AU - Daneshmand, Siamak
AU - Djaladat, Hooman
N1 - Publisher Copyright:
© 2023, International Braz J Urol. All Rights Reserved.
PY - 2023/5
Y1 - 2023/5
N2 - Purpose: To evaluate the perioperative mortality and contributing variables among patients who underwent radical cystectomy (RC) for bladder cancer in recent decades, with comparison between modern (after 2010) and premodern (before 2010) eras. Materials and Methods: Using our institutional review board-approved database, we reviewed the records of patients who underwent RC for primary urothelial bladder carcinoma with curative intent from January 2003 to December 2019. The primary and secondary outcomes were 90 and 30-day mortality. Univariate and multivariable logistic regression models were applied to assess the impact of perioperative variables on 90-day mortality. Results: A total of 2047 patients with a mean±SD age of 69.6±10.6 years were included. The 30 and 90-day mortality rates were 1.3% and 4.9%, respectively, and consistent during the past two decades. Among 100 deaths within 90 days, 18 occurred during index hospitalization. Infectious, pulmonary, and cardiac complications were the leading mortality causes. Multivariable analysis showed that age (Odds Ratio: OR 1.05), Charlson comorbidity index ≥ 2 (OR 1.82), blood transfusion (OR 1.95), and pathological node disease (OR 2.85) were independently associated with 90-day mortality. Nevertheless, the surgical approach and enhanced recovery protocols had no significant effect on 90-day mortality. Conclusion: The 90-day mortality for RC is approaching five percent, with infectious, pulmonary, and cardiac complications as the leading mortality causes. Older age, higher comorbidity, blood transfusion, and pathological lymph node involvement are independently associated with 90-day mortality.
AB - Purpose: To evaluate the perioperative mortality and contributing variables among patients who underwent radical cystectomy (RC) for bladder cancer in recent decades, with comparison between modern (after 2010) and premodern (before 2010) eras. Materials and Methods: Using our institutional review board-approved database, we reviewed the records of patients who underwent RC for primary urothelial bladder carcinoma with curative intent from January 2003 to December 2019. The primary and secondary outcomes were 90 and 30-day mortality. Univariate and multivariable logistic regression models were applied to assess the impact of perioperative variables on 90-day mortality. Results: A total of 2047 patients with a mean±SD age of 69.6±10.6 years were included. The 30 and 90-day mortality rates were 1.3% and 4.9%, respectively, and consistent during the past two decades. Among 100 deaths within 90 days, 18 occurred during index hospitalization. Infectious, pulmonary, and cardiac complications were the leading mortality causes. Multivariable analysis showed that age (Odds Ratio: OR 1.05), Charlson comorbidity index ≥ 2 (OR 1.82), blood transfusion (OR 1.95), and pathological node disease (OR 2.85) were independently associated with 90-day mortality. Nevertheless, the surgical approach and enhanced recovery protocols had no significant effect on 90-day mortality. Conclusion: The 90-day mortality for RC is approaching five percent, with infectious, pulmonary, and cardiac complications as the leading mortality causes. Older age, higher comorbidity, blood transfusion, and pathological lymph node involvement are independently associated with 90-day mortality.
KW - Cystectomy
KW - Neoadjuvant Therapy
KW - Robotic Surgical Procedures
KW - Urinary Bladder Neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85159244986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159244986&partnerID=8YFLogxK
U2 - 10.1590/S1677-5538.IBJU.2022.0405
DO - 10.1590/S1677-5538.IBJU.2022.0405
M3 - Article
C2 - 37115179
AN - SCOPUS:85159244986
SN - 1677-5538
VL - 49
SP - 351
EP - 358
JO - International Braz J Urol
JF - International Braz J Urol
IS - 3
ER -